comparemela.com

Latest Breaking News On - Renexxion - Page 1 : comparemela.com

Renexxion Ireland Limited: Renexxion Ireland Ltd and Dr Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis

Randomized, double-blind, placebo-controlled study to evaluate efficacy of novel pan-GI prokinetic in patients with gastroparesis ROSCREA, Ireland and FREIBURG, Germany, Feb. 15, 2023 /PRNewswire/

North tipperaryDennis riedlFalk pharmaPeter milnerCatherine pearsonRoland greinwaldFalk pharma gmbRenexxion irelandPrnewswire renexxion irelandIreland limitedFalk pharma gmbhManaging director medicineGreater europeChief operating officer

Renexxion Ireland Ltd: Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients

ROSCREA, Ireland, Jan. 10, 2023 /PRNewswire/ - Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet

North tipperaryDhiren patelKostenloser wertpapierhandelPeter milnerCatherine pearsonGastroenterology at stanford university school of medicineDrug administrationCf foundationLouis university school of medicineRenexxion ireland limitedRenexxion irelandIreland limitedInvestigational new drugOpinion leadersZachary sellersAssistant professor

Renexxion Ireland Ltd : Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal disorders

ROSCREA, Ireland, Dec. 23, 2021 /PRNewswire/ Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal

United statesUnited kingdomNorth tipperaryKostenloser wertpapierhandelPeter milnerCatherine pearsonPrnewswire renexxion ireland ltdRenexxion ireland ltdIreland ltdGreater europeCentral asian republicsGreater chinaChief operating officer

vimarsana © 2020. All Rights Reserved.